A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A
Latest Information Update: 08 Feb 2025
Price :
$35 *
At a glance
- Drugs Peboctocogene camaparvovec (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; First in man
- Acronyms Get8; Shuttle
- Sponsors Bayer; Dimension Therapeutics
- 16 Dec 2024 Planned End Date changed from 30 Nov 2026 to 3 Nov 2026.
- 12 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2022 Planned End Date changed from 28 Jun 2027 to 30 Nov 2026.